Drug intelligence / Profile preview

millepachine

Development stage
Preclinical
Lead developer
State Key Laboratory of Biotherapy
Modality
Small Molecules
Administration
Intravenous
01

Overview

Millepachine is a **natural chalcone compound** derived from *Millettia pachycarpa* Benth, exhibiting **antitumor activity primarily via inhibition of topoisomerase II and tubulin polymerization**.[1][2] It operates through dual mechanisms: (1) it **irreversibly inhibits the colchicine-binding site of β-tubulin**, disrupting microtubule assembly and inducing G2/M cell cycle arrest; (2) it **inhibits topoisomerase II**, stabilizing the topoisomerase II-DNA cleavable complex, causing DNA double-strand breaks and apoptosis in tumor cells. Millepachine has demonstrated activity against multiple cancer cell lines, including ovarian and hepatocellular carcinoma, and can overcome multidrug resistance in in vitro models.[1][2][3][4] Importantly, **NF-κB pathway activation** occurs following DNA damage induced by millepachine, contributing to pro-apoptotic effects in tumor cells.[1] Amino acid prodrugs and other derivatives of millepachine have been synthesized to enhance its solubility and antitumor potency.[3][4]

Other names
MIL
02

Targets

TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on millepachine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on millepachine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call